|
|
Genomic Analysis of the CALERIE Trial to Generate New Knowledge for Geroscience |
| 5 R01 AG061378-03 |
|
NIA |
2021 |
|
|
ApoE2 and protective molecular signatures in Alzheimers disease and aging |
| 5 R01 AG061853-04 |
|
NIA |
2021 |
|
|
Ensuring Access to Novel Alzheimer’s and Dementia Treatments: Evaluating Innovative Payment Approaches |
| 5 R01 AG062277-04 |
|
NIA |
2021 |
|
|
Systematic elucidation of endosomal trafficking as a therapeutic opportunity in AD using CRISPR-based functional genomics |
| 5 R01 AG062359-04 |
|
NIA |
2021 |
|
|
Statistical method for neural mechanism mediating and moderating cognitive system in Alzheimers disease and aging research. |
| 5 R01 AG062578-02 |
|
NIA |
2021 |
|
|
Defining the Mechanisms by Which MS4A Genes Regulate TREM2 in Alzheimer Disease |
| 5 R01 AG062734-03 |
|
NIA |
2021 |
|
|
Statistical methods to improve reproducibility and reduce technical variability in heterogeneous multimodal neuroimaging studies of Alzheimer’s Disease |
| 5 R01 AG063752-03 |
|
NIA |
2021 |
|
|
Higher Reimbursements for Primary Care Services and the Quality of Care for Dually-Eligible Nursing Home Residents with Alzheimer's Disease and Related Dementias. |
| 5 R01 AG063935-02 |
|
NIA |
2021 |
|
|
Personalized genetic profiles of risk and resilience in Alzheimers and vascular diseases |
| 5 R01 AG065477-02 |
|
NIA |
2021 |
|
|
Health, Wellbeing, and the Social Networks of Family Caregivers of People with Alzheimers Disease |
| 5 R01 AG066194-03 |
|
NIA |
2021 |
